Copyright ©2014 Baishideng Publishing Group Inc.
1948-5182. Jun 27, 2014; 6(6): 419-425
Published online Jun 27, 2014. doi: 10.4254/wjh.v6.i6.419
Table 2 Current recommendations for antiviral treatment of hepatitis C virus infection in maintenance hemodialysis patients with kidney failure[1,54,56,57]
ST-IFNα-2a3 million units, three times a weekUsually 48 wk for HCV genotypes 1 and 4, and 24 wk for HCV genotypes 2 and 3, or receiving response-guided treatment A more reduced dose, a longer interval between two injections, or temporary cessation of IFNα should be considered in patients with severe side effects such as dangerous bone marrow suppression
ST-IFNα-2b3 million units, three times a week
PEG-IFNα-2a135 μg, once a week
PEG-IFNα-2b1 μg/kg, once a week
Ribavirin200 mg, once a day, every other day, or thrice weekly after hemodialysisRibavirin is applied in combination with interferon, and should be prohibited if severe anemia or other adverse effects occurs